Eight months after reaching its goal of becoming entirely consumer health-focused, Perrigo Company PLC checks another box on its list with approval of its first national brand OTC product, Nasonex 24HR Allergy.
Perrigo Debuts On US National Brand Stage With OTC Switch Approval For Nasonex 24HR Allergy
Nasonex 24HR Allergy also will be first OTC mometasone furoate product available in US. It will compete in OTC intranasal corticosteroids category already led by other brands switched from Rx to nonprescription over past eight years.
